Stent placement in perihilar cholangiocarcinoma

Queen, Thomas; Adler, Douglas G.

doi:10.1002/cld.323

Cited by 2 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the complications of stent therapy includes clogging with stones or obstruction with tumor ingrowth or overgrowth [48]. Despite complications, stenting can improve the quality of life in patients with cholangiocarcinoma (Table 1) [42].…”

Section: Endoscopymentioning

confidence: 99%

Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma

Renzulli

Ramai

Singh

et al. 2021

Cancers

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) is a primary and aggressive cancer of the biliary tree. Combined hepatocellular cholangiocarcinoma (CHC) is a distinctive primary liver malignancy which has properties of both hepatocytic and cholangiocytic differentiation. CHC appears to have a worse prognosis compared to hepatocellular carcinoma, and similar to that of intrahepatic CCA. While significant advances have been made in understanding the pathophysiology and treatment of these two tumor types, their prognosis remains poor. Currently, liver resection is the primary treatment modality; however, only a minority of patients are eligible for surgery. However, the use of locoregional therapies proves an alternative approach to treating locally advanced disease with the aim of converting to resectability or even transplantation. Locoregional therapies such as transarterial chemoembolization (TACE), selective internal radiation therapy (SIRT), radiofrequency ablation (RFA), and photodynamic therapy (PDT) can provide patients with tumor control and increase the chances of survival. In this review, we appraise the evidence surrounding the use of locoregional therapies in treating patients with CCA and CHC.

show abstract

Section: Endoscopymentioning

confidence: 99%

Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma

Renzulli

Ramai

Singh

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…In the context of unresectable disease, it may be performed percutaneously or endoscopically (with stenting) depending on institutional experience, anatomical and biological factors, and the presence of cholangitis [ 80 ]. Tumour progression can lead to decreased stent patency requiring stent replacement [ 81 ]. Several studies have shown prolonged stent patency with the use of local therapies, including intraluminal brachytherapy and radiofrequency ablation (both with and without chemotherapy), leading to improved outcomes in patients [ 82 , 83 , 84 , 85 ].…”

Section: Systemic Therapy For Unresectable Advanced or Metastatic Bil...mentioning

confidence: 99%

A Practical Guide for the Systemic Treatment of Biliary Tract Cancer in Canada

et al. 2023

View full text Add to dashboard Cite

Biliary tract cancers (BTC) are rare and aggressive tumors with poor prognosis. Radical surgery offers the best chance for cure; however, most patients present with unresectable disease, and among those receiving curative-intent surgery, recurrence rates remain high. While other locoregional therapies for unresectable disease may be considered, only select patients may be eligible. Consequently, systemic therapy plays a significant role in the treatment of BTC. In the adjuvant setting, capecitabine is recommended following curative-intent resection. In the neoadjuvant setting, systemic therapy has mostly been explored for downstaging in borderline resectable tumours, although evidence for its routine use is lacking. For advanced unresectable or metastatic disease, gemcitabine-cisplatin plus durvalumab has become the standard of care, while the addition of pembrolizumab to gemcitabine-cisplatin has also recently demonstrated improved survival compared to chemotherapy alone. Following progression on gemcitabine-cisplatin, several chemotherapy combinations and biomarker-driven targeted agents have been explored. However, the optimum regimen remains unclear, and access to targeted agents remains challenging in Canada. Overall, this article serves as a practical guide for the systemic treatment of BTC in Canada, providing valuable insights into the current and future treatment landscape for this challenging disease.

show abstract

Stent placement in perihilar cholangiocarcinoma

Cited by 2 publications

References 24 publications

Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma

Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma

A Practical Guide for the Systemic Treatment of Biliary Tract Cancer in Canada

Contact Info

Product

Resources

About